Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9
Sachse-Seeboth, C. ; Pfeil, J. ; Sehrt, D. ; Meineke, I. ; Tzvetkov, M. ; Bruns, E. ; Poser, W. ; Vormfelde, S. V. et al.
Zitierfähiger Link (URL): http://resolver.sub.uni-goettingen.de/purl?gs-1/6077
The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered Δ9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9*2 allele status. However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes. CYP2C9*3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC.